S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
Argentina's populist president meets billionaire Elon Musk in Texas — and a bromance is born
NASDAQ:ALXO

ALX Oncology (ALXO) Stock Price, News & Analysis

$13.03
-0.35 (-2.62%)
(As of 04/12/2024 ET)
Today's Range
$12.51
$13.63
50-Day Range
$10.72
$16.79
52-Week Range
$3.94
$17.42
Volume
359,332 shs
Average Volume
465,540 shs
Market Capitalization
$653.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.83

ALX Oncology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
44.5% Upside
$18.83 Price Target
Short Interest
Bearish
11.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of ALX Oncology in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$223,000 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.33) to ($2.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.49 out of 5 stars

Medical Sector

496th out of 923 stocks

Pharmaceutical Preparations Industry

231st out of 430 stocks

ALXO stock logo

About ALX Oncology Stock (NASDAQ:ALXO)

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALXO Stock Price History

ALXO Stock News Headlines

My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
ALX Oncology (NASDAQ:ALXO) Shares Gap Up to $12.14
ALX Oncology (NASDAQ:ALXO) Earns Buy Rating from HC Wainwright
My biggest AI fear
These 10 stocks have the power to make you a millionaire as early as 2026… And all you need is $10K. Investing in each of the stocks in The AI Millionaire Blueprint could make a 9,900% return in as little as the next three years.
Alx Oncology CEO buys $49.7k in company shares
ALXO Apr 2024 7.000 put
ALXO Apr 2024 19.000 call
ALXO Apr 2024 14.000 put
ALX Oncology just downgraded at Stifel, here's why
ALX Oncology Holdings Inc.
ALX Oncology: Major Caution Warranted Moving Forward
See More Headlines
Receive ALXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALX Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/13/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ALXO
Fax
N/A
Employees
72
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.83
High Stock Price Target
$27.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+44.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-160,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.81 per share

Miscellaneous

Free Float
24,925,000
Market Cap
$653.45 million
Optionable
Optionable
Beta
1.58
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Corey S. Goodman Ph.D. (Age 72)
    Executive Chairman
    Comp: $84k
  • Mr. Jason W. LettmannMr. Jason W. Lettmann (Age 47)
    CEO & Director
    Comp: $60.5k
  • Dr. Jaume Pons Ph.D. (Age 57)
    Founder, President, Director & Chief Scientific Officer
    Comp: $856.29k
  • Mr. Peter S. Garcia M.B.A.Mr. Peter S. Garcia M.B.A. (Age 62)
    Chief Financial Officer
    Comp: $631.11k
  • Dr. Sophia Randolph M.D. (Age 56)
    Ph.D., Chief Medical Officer & Director
    Comp: $637.24k
  • Dr. Michael Chang Ph.D.
    Vice President of Operations
  • Ms. Shelly Pinto (Age 47)
    Senior VP of Finance & Chief Accounting Officer
    Comp: $508.26k
  • Dr. Christopher Byrd J.D.
    Ph.D., General Counsel
  • Dr. Athanasios Tsiatis M.D.
    Senior Vice President of Clinical Development
  • Dr. Lin Yeong-Liang M.D.
    M.S., Senior Vice President of Drug Safety & Pharmacovigilance

ALXO Stock Analysis - Frequently Asked Questions

Should I buy or sell ALX Oncology stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ALX Oncology in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALXO shares.
View ALXO analyst ratings
or view top-rated stocks.

What is ALX Oncology's stock price target for 2024?

7 Wall Street research analysts have issued 12 month target prices for ALX Oncology's shares. Their ALXO share price targets range from $11.00 to $27.00. On average, they predict the company's share price to reach $18.83 in the next year. This suggests a possible upside of 44.5% from the stock's current price.
View analysts price targets for ALXO
or view top-rated stocks among Wall Street analysts.

How have ALXO shares performed in 2024?

ALX Oncology's stock was trading at $14.89 on January 1st, 2024. Since then, ALXO stock has decreased by 12.5% and is now trading at $13.03.
View the best growth stocks for 2024 here
.

Are investors shorting ALX Oncology?

ALX Oncology saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,120,000 shares, an increase of 7.2% from the March 15th total of 2,910,000 shares. Based on an average daily trading volume, of 389,200 shares, the days-to-cover ratio is currently 8.0 days. Currently, 11.5% of the shares of the company are sold short.
View ALX Oncology's Short Interest
.

When is ALX Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ALXO earnings forecast
.

How were ALX Oncology's earnings last quarter?

ALX Oncology Holdings Inc. (NASDAQ:ALXO) announced its quarterly earnings results on Thursday, March, 7th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.09.

What ETF holds ALX Oncology's stock?

Inspire Small/Mid Cap ETF holds 33,156 shares of ALXO stock, representing 0.23% of its portfolio.

What other stocks do shareholders of ALX Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ALX Oncology investors own include Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Innovative Industrial Properties (IIPR), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and

When did ALX Oncology IPO?

ALX Oncology (ALXO) raised $128 million in an initial public offering on Friday, July 17th 2020. The company issued 8,000,000 shares at $15.00-$17.00 per share. Jefferies, Credit Suisse, Piper Sandler and Cantor served as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are ALX Oncology's major shareholders?

ALX Oncology's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.20%). Insiders that own company stock include Jason Lettmann, Jaume Pons, Lsv Associates, Llc, Peter S Garcia, Peter S Garcia, Shelly Pinto and Sophia Randolph.
View institutional ownership trends
.

How do I buy shares of ALX Oncology?

Shares of ALXO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALXO) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners